Back to results
US 12,669,513 B2Granted
Magnetic point-of-care systems and assays for determining GFAP in biological samples
AssigneeAbbott Laboratories
InventorsAntti Virtanen, Cary James Miller, Tony Lee, Peter Karabatsos, Craig Jeffrey, Andrew Schapals, Alison Taylor
Life of this patent
Estimating the term…
Abstract
Disclosed herein are systems and assays that employ magnetically susceptible beads and point-of-care devices comprising magnetic immunosensors to determine the amount of glial fibrillary acidic protein (GFAP) in a biological sample obtained from a subject.
Claims35
An assay for measuring an amount of glial fibrillary acid protein (GFAP) in a biological sample obtained from a subject, comprising:
- performing an assay for GFAP, wherein the assay comprises:
- (a) contacting the sample with a cartridge comprising at least one magnetic immunosensor and (i) at least one first specific binding partner comprising at least one anti-GFAP antibody which is configured to specifically bind to GFAP in the sample, wherein the anti-GFAP antibody that is configured to be printed on the cartridge, wherein said at least one first specific binding partner is configured to be immobilized on at least one magnetically susceptible bead;
- and (ii) at least one second specific binding partner comprising a detectable label that is configured to be printed on the cartridge, thereby producing one or more complexes comprising the first specific binding partner-GFAP-second specific binding partner;
- (b) said assay configured for magnetically capturing and retaining the bead containing the complexes using the at least one magnetic immunosensor;
- and (c)) said assay configured for assessing a signal from the complexes, wherein the amount of detectable signal from the detectable label is configured to indicate the amount of GFAP in the sample, wherein the cartridge is used in a point-of-care device, and further wherein the assay is configured to exhibit at least a 5-fold increase in sensitivity compared to an assay that does not immobilize the first specific binding partner on a magnetically susceptible bead and magnetically capture and retain the bead containing the complexes on at least one magnetic immunosensor in a cartridge used in a point-of-care device.
2 more elements
A system comprising:
- an assay for glial fibrillary acidic protein (GFAP), wherein the assay comprises contacting a biological sample from a subject with a cartridge comprising at least one magnetic immunosensor and (i) at least one first specific binding partner comprising at least one anti-GFAP antibody w which is configured to specifically bind to GFAP in the sample, wherein the anti-GFAP antibody that is configured to be printed on the cartridge, wherein said at least one first specific binding partner is configured to be immobilized on at least one magnetically susceptible bead;
- and (ii) at least one second specific binding partner comprising a detectable label that is configured to be printed on the cartridge, thereby producing one or more complexes comprising the first specific binding partner-GFAP-second specific binding partner;
- a point-of-care device comprising the cartridge, wherein the device (a) is configured to determines an amount of GFAP in a sample obtained from the subject by magnetically capturing and retaining the bead containing the complexes on the at least one magnetic immunosensor;
- and (b) is configured to assess a signal from the complexes, wherein the amount of detectable signal from the detectable label is configured to indicate the amount of GFAP in the sample, wherein the assay is configured to exhibit at least a 5-fold increase in sensitivity compared to an assay that does not immobilize the first specific binding partner on a magnetically susceptible bead and magnetically capture and retain the bead containing the complexes on at least one magnetic immunosensor in a cartridge contained in a point-of-care device.
1 more element
Dependencies are inferred from the claim text.